FDA Panel To Review SonaCare’s HIFU Device For Prostate Cancer
This article was originally published in The Gray Sheet
Executive Summary
It will be the second time this year that the Gastroenterology and Urology Devices Panel reviews a high intensity focused ultrasound system intended for prostate cancer. SonaCare is surely hoping for a better showing for its Sonablate 450 than EDAP experienced last month with its Ablatherm HIFU.
You may also be interested in...
FDA Panel Rejects Sonablate 450 HIFU Device For Prostate Cancer
The advisors voted almost unanimously that SonaCare Medical’s HIFU device did not have good enough data to support a positive risk-benefit profile, but they suggested the company could improve their trial design and try again.
Advancing Ablative Tumor Therapies Into Primary Treatments
For many cancers, there is a need for a third option between the two current choices of radical tissue destruction and watchful waiting. New cancer ablation devices in development have the potential to fill that gap. Ablative tumor therapies can play a role in eradication of early-stage and localized tumors, as salvage therapies in patients who've failed other therapies, and for patients whose health precludes surgery or further radiation. Ablation has many advantages. It's a cost-effective and minimally invasive alternative to robotic surgery or radiation devices, and may lead to fewer side effects and complications than current primary tumor treatments. But proving that ablation can save lives compared to more radical forms of therapy requires clinical evidence from multiyear outcome trials that few smaller companies are willing to invest in. There's little evidence to date that venture investors will see returns. But the race is on among companies hoping to become the first device approved for low-risk, localized prostate cancer, a potentially game-changing event.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.